CB‐103: A novel CSL‐NICD inhibitor for the treatment of NOTCH‐driven T‐cell acute lymphoblastic leukemia: A case report of complete clinical response in a patient with relapsed and refractory T‐ALL

Autor: Michael Medinger, Till Junker, Dominik Heim, Alexandar Tzankov, Philip M. Jermann, Maria Bobadilla, Michele Vigolo, Rajwinder Lehal, Florian D. Vogl, Michael Bauer, Jakob Passweg

Publikováno v: eJHaem, Vol 3, Iss 3, Pp 1009-1012 (2022)

Abstract Relapsed T cell acute lymphoblastic leukaemia (T‐ALL) has a very poor prognosis. A 24‐year‐old patient with relapsed high‐risk T‐ALL (PTEN gene deletion; NOTCH1 mutation), was treated with the NOTCH inhibitor CB‐103. Within 1 wee

Externí odkaz: https://doaj.org/article/06e153db5bae43668267f8a8964d3c11

Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study

Autor: Alfredo Addeo, Sacha I. Rothschild, Lisa Holer, Martina Schneider, Christine Waibel, Simon Haefliger, Michael Mark, Eugenio Fernandez, Nicolas Mach, Laetitia Mauti, Philip M. Jermann, Ilaria Alborelli, Byron Calgua, Spasenija Savic-Prince, Markus Joerger, Martin Früh

Publikováno v: Addeo, Alfredo; Rothschild, Sacha I; Holer, Lisa; Schneider, Martina; Waibel, Christine; Haefliger, Simon; Mark, Michael; Fernandez, Eugenio; Mach, Nicolas; Mauti, Laetitia; Jermann, Philip M; Alborelli, Ilaria; Calgua, Byron; Savic-Prince, Spasenija; Joerger, Markus; Früh, Martin (2022). Fibroblast growth factor receptor (FGFR) inhibitor rogaratinib in patients with advanced pretreated squamous-cell non-small cell lung cancer over-expressing FGFR mRNA: The SAKK 19/18 phase II study. Lung cancer, 172, pp. 154-159. Elsevier 10.1016/j.lungcan.2022.08.016

BACKGROUND Patients with advanced squamous-cell lung cancer (SQCLC) frequently (46%) exhibit tumor overexpression of fibroblast growth factor receptor (FGFR) messenger ribonucleic acid (mRNA). Rogaratinib is a novel oral pan-FGFR inhibitor with a goo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8ce6fec7ed70590a5c75fdb00a5b404
https://doi.org/10.1016/j.lungcan.2022.08.016

Preanalytical Variables and Sample Quality Control for Clinical Variant Analysis

Autor: Ilaria, Alborelli, Philip M, Jermann

Publikováno v: Methods in molecular biology (Clifton, N.J.). 2493

Broad molecular profiling by next-generation sequencing of solid tumors has become a critical tool for clinical decision-making in the era of precision oncology. In addition to many already approved targeted therapies, more than half of ongoing oncol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::5762dda6a3b1e514fe72a1ca2731c47a
https://pubmed.ncbi.nlm.nih.gov/35751825

Establishing standardized immune phenotyping of metastatic melanoma by digital pathology

Autor: Bettina Sobottka, Marta Nowak, Anja Laura Frei, Martina Haberecker, Samuel Merki, Mitchell P. Levesque, Reinhard Dummer, Holger Moch, Viktor Hendrik Koelzer, Rudolf Aebersold, Melike Ak, Faisal S. Al-Quaddoomi, Jonas Albinus, Ilaria Alborelli, Sonali Andani, Per-Olof Attinger, Marina Bacac, Daniel Baumhoer, Beatrice Beck-Schimmer, Niko Beerenwinkel, Christian Beisel, Lara Bernasconi, Anne Bertolini, Bernd Bodenmiller, Ximena Bonilla, Ruben Casanova, Stéphane Chevrier, Natalia Chicherova, Maya D'Costa, Esther Danenberg, Natalie Davidson, Monica-Andreea Drăganmoch, Stefanie Engler, Martin Erkens, Katja Eschbach, Cinzia Esposito, André Fedier, Pedro Ferreira, Joanna Ficek, Bruno Frey, Sandra Goetze, Linda Grob, Gabriele Gut, Detlef Günther, Pirmin Haeuptle, Viola Heinzelmann-Schwarz, Sylvia Herter, Rene Holtackers, Tamara Huesser, Anja Irmisch, Francis Jacob, Andrea Jacobs, Tim M. Jaeger, Katharina Jahn, Alva R. James, Philip M. Jermann, André Kahles, Abdullah Kahraman, Werner Kuebler, Jack Kuipers, Christian P. Kunze, Christian Kurzeder, Kjong-Van Lehmann, Sebastian Lugert, Gerd Maass, Markus G. Manz, Philipp Markolin, Julien Mena, Ulrike Menzel, Julian M. Metzler, Nicola Miglino, Emanuela S. Milani, Simone Muenst, Riccardo Murri, Charlotte K.Y. Ng, Stefan Nicolet, Patrick G.A. Pedrioli, Lucas Pelkmans, Salvatore Piscuoglio, Michael Prummer, Mathilde Ritter, Christian Rommel, María L. Rosano-González, Gunnar Rätsch, Natascha Santacroce, Jacobo Sarabia del Castillo, Ramona Schlenker, Petra C. Schwalie, Severin Schwan, Tobias Schär, Gabriela Senti, Franziska Singer, Sujana Sivapatham, Berend Snijder, Vipin T. Sreedharan, Stefan Stark, Daniel J. Stekhoven, Alexandre P.A. Theocharides, Tinu M. Thomas, Markus Tolnay, Vinko Tosevski, Nora C. Toussaint, Mustafa A. Tuncel, Marina Tusup, Audrey Van Drogen, Marcus Vetter, Tatjana Vlajnic, Sandra Weber, Walter P. Weber, Rebekka Wegmann, Michael Weller, Fabian Wendt, Norbert Wey, Andreas Wicki, Mattheus HE Wildschut, Bernd Wollscheid, Shuqing Yu, Johanna Ziegler, Marc Zimmermann, Martin Zoche, Gregor Zuend

Publikováno v: Laboratory Investigation; a Journal of Technical Methods and Pathology

CD8+ tumor-infiltrating T cells can be regarded as one of the most relevant predictive biomarkers in immune-oncology. Highly infiltrated tumors, referred to as inflamed (clinically “hot”), show the most favorable response to immune checkpoint inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d74ecfeeb15c1b4897606a94b52a648

Development and Characterization of an Enzymatic Method for the Rapid Determination of Gamma Hydroxybutyric Acid

Autor: Michel A. Sciotti, Lara Hasan, André Scholer, Thomas M. Jermann, Jakob M. Weber, Daniel Gygaxa

Publikováno v: CHIMIA, Vol 64, Iss 11 (2010)

Gamma hydroxybutyric acid (GHB) is a regulated therapeutic drug, which naturally occurs in mammalian brain tissues as an intermediate of the GABA (gamma aminobutyric acid) neurotransmitter metabolism. The increasing misuse of GHB as a narcotic or abu

Externí odkaz: https://doaj.org/article/405ccbf1da6845849ad4084474946251